Government Launches Consultation on Future of UK Human Fertilisation and Tissue Regulators
By Ayesha Ahmad,
BioNews
| 07. 02. 2012
The UK Government has launched a consultation on the future of the Human Fertilisation and Embryology Authority (HFEA) and Human Tissue Authority (HTA) amid proposals to transfer the regulators' functions elsewhere.
The UK-wide consultation asks for views on whether the HFEA and HTA should be abolished and the regulator's responsibilities reallocated to the Care Quality Commission (CQC), with the HFEA's research functions transferred to the newly formed Health Research Authority – or if some functions should be transferred to organisations other than the CQC. It also asks for views on whether the HFEA and HTA should continue to retain their functions, with further cost-savings made.
Read more...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
